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Abstract: Introduction: The influence of n-3 long-chain polyunsaturated fatty acids (n-3 LCPUFA)
supplementation on health outcomes has been studied extensively with randomized controlled
trials (RCT). In many research fields, difficulties with recruitment, adherence and high drop-out
rates have been reported. However, what is unknown is how common these problems are in n-3
LCPUFA supplementation studies in children and adolescents. Therefore, this paper will review n-3
LCPUFA supplementation studies in children and adolescents with regard to recruitment, adherence
and drop-out rates. Methods: The Web of Science, PubMed and Ovid databases were searched
for papers reporting on RCT supplementing children and adolescents (2–18 years) with a form of
n-3 LCPUFA (or placebo) for at least four weeks. As a proxy for abiding to CONSORT guidelines,
we noted whether manuscripts provided a flow-chart and provided dates defining the period of
recruitment and follow-up. Results: Ninety manuscripts (reporting on 75 studies) met the inclusion
criteria. The majority of the studies did not abide by the CONSORT guidelines: 55% did not provide a
flow-chart, while 70% did not provide dates. The majority of studies provided minimal details about
the recruitment process. Only 25 of the 75 studies reported an adherence rate which was on average
85%. Sixty-five of the 75 studies included drop-out rates which were on average 17%. Conclusion:
Less than half of the included studies abided by the CONSORT guidelines (45% included a flow
chart, while 30% reported dates). Problems with recruitment and drop-out seem to be common in n-3
LCPUFA supplementation trials in children and adolescents. However, reporting about recruitment,
adherence and dropout rates was very heterogeneous and minimal in the included studies. Some
techniques to improve recruitment, adherence and dropout rates were identified from the literature,
however these techniques may need to be tailored to n-3 LCPUFA supplementation studies in children
and adolescents.
Keywords: recruitment; adherence; drop-out rates; omega-3 fatty acids; children; adolescents
1. Introduction
Fatty acids, and especially the omega-3 long-chain polyunsaturated fatty acids (n-3 LCPUFA), are
being researched extensively for a wide array of health outcomes varying from, but not exclusive to,
cardiovascular diseases, depression and cognition [1–3]. As in every health related field, randomized
controlled supplementation trials are the gold standard to demonstrate efficacy of n-3 LCPUFA [4]. For
these trials, voluntary participants are needed, however recruitment of participants can be challenging,
especially when it involves research in children and adolescents (<18 years) [5]. It has been reported
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that less than 31% of British studies funded by two funding bodies between 1994 and 2002 achieved
their original recruitment target number [6]. Similarly, others have reported that up to 60% of the
randomized controlled trials (RCT) fail to meet their participant target or need an extension [7] and
this percentage might be even higher in paediatric and adolescent studies [8,9]. However, even
after the recruitment phase, difficulties with conducting research do not end, because drop-out and
non-adherence are also common. Drop-out in RCT is normal and attrition rates can vary enormously
from 0 up to 65% [10–12]. Compliance and adherence are often used interchangeably, but are not
the exactly same. Compliance is the extent to which the behaviour of a person coincides with the
advice given by a doctor or researcher. The term compliance has received criticism because of its
paternalistic connotation [13] and because it implies patient passivity [14]. As a more neutral term,
adherence has been suggested, which presumes that the person agrees with the advice given by a
doctor or researcher [14]. We choose to use the term adherence in the current manuscript. Adherence
issues, are common, with non-adherence ranging anywhere from 3.5 to 80% [15,16]. One must also
be aware that there is no one single definition of adherence. This means that somebody who is
considered non-adherent in one study, might be considered adherent in another (e.g., one study
defined a participant as non-adherent when the participant took less than 75% of the prescribed
medicine or supplements, while another used a cut-off level of <80%). As low recruitment rates, high
drop-out and high non-adherence are common and have serious consequences [6,17,18], it is important
to study factors which possibly affect recruitment, drop-out, and adherence rates.
In 2013, we started a one-year long double blind randomized n-3 LCPUFA supplementation
trial in healthy Dutch adolescents called Food2Learn [19]. We experienced difficulties in the
recruitment, drop-out and adherence of the study participants. Furthermore, many other n3- LCPUFA
supplementation studies have had the same difficulties (personal communication). However, a review
of recruitment, adherence and drop-out rates in nutrition interventions and in specific n-3 LCPUFA
supplementation studies in children and adolescents does not, to our knowledge, exist. Therefore,
the aim is to execute a thorough review to summarize n-3 LCPUFA supplementation studies in
children (2–12 years) and adolescents (12–18 years) with regard to recruitment effort, drop-out and
adherence rates.
2. Materials and Methods
The Web of Science, PubMed and Ovid databases were searched up to 2 March 2017. We searched
for human clinical trials including children aged between 2 and 18 years. We used the search terms:
“Omega-3”, “DHA”, “EPA”, “LCPUFA” and “PUFA” in combination with “RCT”, “randomized
controlled trial”, “supplementation”, “trial” or “fish oil” and “child*)“, “adolescent”, “school”,
“preschool” or “toddler”. Furthermore, a myriad of reviews were checked for additional studies [20–40]
and reference lists of all articles were hand checked for additional references. Moreover, a search of
the Cochrane library was also conducted to identify reviews regarding n-3 LCPUFA supplementation.
The studies included in the Cochrane reviews were checked for inclusion in the current study [41–56].
Lastly, for all included articles, the “cited by” option of Web of Science was checked (this option gives
all articles that cite that specific article).
Studies were eligible for inclusion if they met the following criteria: (1) participants were
aged between 2 and 18 years; (2) the study was a randomized placebo controlled n-3 LCPUFA
supplementation trial; (3) the trial had at least 10 participants per treatment arm; (4) supplementation
duration was at least 4 weeks; and (5) studies were published in English.
All papers were scanned by the first author, and the following information was extracted and
entered in a database:
Participants’ characteristics: Age range of participants, percentage of girls, healthy participants or
those with a diagnosed disease, and country in which the study was executed;
Study characteristics: Number of participants, number of measurement moments (i.e., how often
did participants have to come to the research facility/how often did they have to fill out questionnaires),
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number of measurements, treatment condition, placebo condition, form of supplementation, if capsules
were used then how many, if supplementation was taken under supervision, if supplement was taken
in multiple dosages or once a day, whether an incentive was provided, duration of the study, manner
in which adherence was assessed, adherence rate, whether fatty acids were determined in blood, and
percentage of people who quit the treatment (hereafter called drop-out); and
Recruitment characteristics: Invited/responded or screened, started, finished as well as method
of recruitment, recruitment setting, and study period.
The recruitment characteristics were defined as follows:
Invited: The total number of potential participants invited to participate;
Responded: The total number of potential participants who responded to the invitation or the number
of participants that were screened for participation in the study; and
Started: The number of participants who were assessed as eligible and began supplementation.
Furthermore, efficiency percentages were calculated, namely: started/invited (dividing the
number of people who started by the number of people who were invited times 100), started/
responded (dividing the number of people who started by the number of people who responded
times 100) and started/finished (dividing the number of people who finished by the number of people
who started times 100).
As a proxy for adherence to the CONSORT guidelines, we noted whether the article included a
flow-chart and whether the article provided the dates defining the period of recruitment and follow-up.
Statistics
All extracted data were entered in SPSS (IBM SPPS statistics for Windows, version 24, Armonk,
NY, USA). SPSS was used to calculate averages and SDs for the participant’ characteristics, study
characteristics and recruitment characteristics. For comparison reasons outpatient clinics and hospitals
were combined into one setting, which was named “hospital setting”. Countries were furthermore
grouped in regions for comparisons (Europe, USA/Canada, Asia, Middle East, Australia, Africa and
South America). When a study mentioned multiple compliance rates, these were combined into one
compliance rate for the whole study.
3. Results
3.1. Study Characteristics
The original search led to 2163 hits. Upon first screening, 1656 articles were excluded, additional
screening of the whole articles led to a further exclusion of 173 articles. Additional checking of the
reference lists of reviews, included articles and forward checking led to 15 more studies being included
(see Figure 1, adapted from [57]). Thus, in total, 90 papers, describing 75 studies, were included in this
review. The characteristics of these studies can be found in Table 1. Fifteen studies focussed on healthy
children. The other 60 studies focused on children with a disorder or disease, with attention deficit
hyperactivity disorder (ADHD) being the most studied disorder (n = 21) (see Table 1). The majority of
studies focussed on children (defined as aged between 2 and 12 years, n = 38) or both children and
adolescents (n = 31). A minority of studies focussed only on adolescents (n = 6) (see Table 1). Duration
of study varied from 4 to 52 weeks, with the majority of studies lasting 26 weeks or less (n = 59, 79%,
see Table 2. Number of measurement moments (i.e., how often did participants have to come to the
research facility/how often did they have to fill out questionnaires) varied from 2 to 16 with a mean of
3.7 (SD 2.7), the number of different measurements per moment varied from 1 to 19 with a mean of 4.9
(SD 3.7).
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Figure 1. Flow diagram of study selection: 90 manuscripts were found reporting on 75 studies.  
Table 1. Characteristics of studies. 
Reference  Age Range or Mean (SD) Gender (%Female) Population: Healthy, Disorder or Disease  Country
[58] 3–15 44 Acute lymphoblastic leukemia Egypt  
[59] 6–12 25 ADHD Iran 
[60] 7–15 NR ADHD Iran 
[61] 11–12 31 ADHD Canada 
[62] 8–14 0 ADHD  The Netherlands 
[63] 6–16 41 (after intervention)  ADHD Israel 
[64] 7–12 20 ADHD Sweden 
[65] 6–12 38 ADHD Iran 
[66] 6–12 NR ADHD Japan 
[67,68] 8–18 15 ADHD Sweden 
[69] 12–16 0 ADHD UK 
[70,71] 6–13 23 ADHD Australia 
[72] 6–12 27 ADHD Sri Lanka 
[73] 7–13 41 ADHD Israel  
[74,75] 7–12 23 ADHD Australia 
[76] 6–13 13 ADHD USA 
[77] 8–13 25 ADHD Israel 
[78] 6–12 22 ADHD USA 
[79] 6–12 22 ADHD Germany 
[80,81] 6–13 34 ADHD Israel 
[82] 7–12 43 (after intervention) ADHD or lower IQ China 
[83] 6–14 15 ADHD Australia 
[84] 6.9–11.9 NR ADHD Canada 
[85] 8–16 48 Aggressive behaviour Mauritius 
[86] 6–14 42 Asthma  USA 
[87] 8–12 56 Asthma  Australia 
[88] 10–12 31 Asthma  Taiwan 
[89] 10.2 (2.5) fish oil, 11.9 (3.1) 48 Bronchial asthma Japan 
Figure 1. Flow diagram of study selection: 90 manuscripts were found reporting on 75 studies.
Table 1. Characteristi f t i .
Reference Age Range orMean (SD) Gender (%Female)
Population: Healthy,
Disorder or Disease Country
[58] 3–15 44 Acute lymphoblasticleukemia Egypt
[59] 6–12 25 ADHD Iran
[60] 7–15 NR ADHD Iran
[61] 11–12 31 ADHD Canada
[62] 8–14 0 ADHD The Netherlands
[63] 6–16 41 (after intervention) ADHD Israel
[64] 7–12 20 ADHD Sweden
[65] 6–12 38 ADHD Iran
[66] 6–12 NR ADHD Japan
[67,68] 8–18 15 ADHD Sweden
[69] 12–16 0 ADHD UK
[70,71] 6–13 23 ADHD Australia
[72] 6–12 27 ADHD Sri Lanka
[73] 7–13 41 ADHD Israel
[74,75] 7–12 23 ADHD Australia
[76] 6–13 13 ADHD USA
[77] 8–13 25 ADHD Israel
[78] 6–12 22 ADHD USA
[79] 6–12 22 ADHD Germany
[80,81] 6–13 34 ADHD Israel
[82] 7–12 43 (after intervention) ADHD or lower IQ China
[83] 6–14 15 ADHD Australia
[84] 6.9–11.9 NR ADHD Canada
[85] 8–16 48 Aggressive behaviour Mauritius
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Table 1. Cont.
Reference Age Range orMean (SD) Gender (%Female)
Population: Healthy,
Disorder or Disease Country
[86] 6–14 42 Asthma USA
[87] 8–12 56 Asthma Australia
[88] 10–12 31 Asthma Taiwan
[89] 10.2 (2.5) fish oil,11.9 (3.1) control 48 Bronchial asthma Japan
[90] 3–8 11 Autism USA
[91] 5–8 NR Autism USA
[92] 2–5 26 Autism Canada
[93] 3–10 17 Autism USA
[94] 6–17 48% placebo, 46% flax oil Bipolar disorder USA
[95] 7.3–9.5 54 CF Italy
[96] 5–16 47 Crohn’s disease Italy
[97] 5–12 33 DCD UK
[98] 10.6 43 Dyslexia Finland
[99] 15–18 100 Dysmenorrhea USA
[100] 4–12 NR Epilepsy Egypt
[101] 7–9 53 Healthy South-Africa
[102] 8–14 50 Healthy Indonesia
[103] 9–12 51 Healthy Japan
[104] 9–10 50 Healthy Sweden
[105] 10–12 49 Healthy UK
[106] 8–10 52 Healthy UK
[107] 5–7 NR Healthy Canada
[108] 8–10 0 Healthy USA
[109] 6–10 46 Healthy Australia andIndonesia
[110] 3–13 46 Healthy Australia
[111] 8–14 51 Healthy Spain
[112] 4 47 Healthy USA
[113] 10–12 100 Healthy Turkey
[114] 13–16 50 Healthy UK
[115] 9–12 47 Healthy Thailand
[116] 8–13 47 Hyperlipidaemia Italy
[117] 14 (2) 31 Hypertriglyceridemia andlow LDL USA
[118–121] 6–11 49 Iron deficiency South-Africa
[122] 8–12 15 Literacy problems UK
[123] 8–12 58 Malnourished Mexico
[124] 5–14 56 Migraine Iran
[125] 7–14 NR MDD USA
[126] 6–12 NR MDD Israel
ADHD = attention deficit hyperactivity disorder; NAFL = non-alcoholic fatty liver; MDD = major depressive
disorder; DCD = Developmental Co-ordination Disorder; CF = cystic fibrosis, NR = not reported.
Two studies were published before the start of the CONSORT guidelines. Of the 73 studies that
were published after the start of the CONSORT guidelines, 33 studies (45%) provided a flow diagram
and 22 studies (30%) reported the dates defining the period of recruitment and follow-up.
3.2. Recruitment
Most of the studies included in this review did not report the number of children or adolescents
that were invited to participate in the study, as only 11 out of 75 studies mentioned the number of
participants that were invited. The total number of people invited to participate varied from 46 to 3562
(Mean (M) = 804.5, SD = 1083.28). The percentage of invited participants that eventually started the
study ranged from 2.4 to 87% (see Table 3).
Forty out of 75 studies mentioned the number of participants that responded to the invitation or
were screened for the study and this varied from 30 to 1556, with 12 to 100% of these people actually
starting the study.
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Most studies did not specify the exact method(s) of recruitment, mostly just mentioning the
recruitment setting. Most studies recruited their participants from a hospital or outpatient clinic
setting (n = 33). Other settings from which participants were recruited were schools (n = 23) and the
community (n = 15). Nine studies reported multiple settings for recruitment; one study recruited
participants from a summer camp for children with ADHD and other disorders; one study recruited
from an online registry; one study recruited participants from those who participated in earlier studies;
and eight studies did not mention the recruitment setting.
Looking at the efficiency percentages for started/invited, started/responded or started/finished
for studies including those with an illness (averages 43.5%, 63.5%, and 83.1%, respectively) and
those without (averages 36.2%, 53.1%, and 84.2%, respectively), there was a clear difference for
started/invited and started/responded but not for started/finished. A comparison for average rates
between studies including only children (38.8%, 62.2%, and 85.4%, respectively), only adolescents
(15.5%, 56.4%, and 87.8%, respectively) or both (53.4%, 52.7%, and 79.6%, respectively) showed notable
differences. For different recruitment settings, there were mainly clear differences for started/invited.
However, for all rates, the school setting had the highest average rate: hospital (17.7%, 56.8%, and
82.9%, respectively), community (29.9%, 57.1%, and 81.7%, respectively), and school (46.0%, 64.6%,
and 86.8%, respectively). Lastly, when looking at these average efficiency percentages for the different
continents, we also saw clear differences: Europe (35.3%, 64.3%, and 87.8%, respectively), North
America (6.6%, 48%, and 77.7%, respectively), Asia (49.5%, 48.7%, and 92.6%, respectively), Africa (NA,
28%, and 91.1%, respectively), Middle East (33.2%, 64.6%, and 79%, respectively), Australia (72.9%,
69.5%, and 70.7%, respectively), and South America (54%, 93.2%, and 90.9%, respectively).
3.3. Supplementation
Most studies used capsules as the form of supplementation (n = 57), however there were also
some other approaches (see Table 2). The number of capsules that participants were instructed to take
also varied widely from 1 to 12 capsules a day, with some studies basing the dose per body weight of
the participant (see Table 2). Moreover, a huge range of different placebos was used (see Table 2).
3.4. Adherence
The included studies mentioned a wide variety of methods to measure adherence: capsule count
(or product weighting) (n = 30), diaries or tick-off forms (n = 13), interviews face to face/via phone/
via e-mail (n = 11), taking the capsules under supervision (n = 8), and blood values (n = 5) (see Table 4).
Thirteen studies used more than one method to assess adherence. Furthermore, 23 studies did not
specify how or whether they assessed adherence. The way in which adherence was reported in the
studies also varied greatly. Some studies mentioned percentages of capsules taken, the average number
of capsules taken per day, blood values, or just mentioned that adherence was good or mentioned how
many students were excluded due to non- adherence.
Twenty-five studies mentioned a specific percentage of adherence, which varied from 60 to 97%,
mean 85% (SD 10.1). In addition, the levels of capsules that needed to be taken to be considered as
being adherent differed per study, varying from 65 to 90%. Other studies defined adherence as the
number of days of not taking capsules.
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Table 2. Treatment characteristics per study.
Reference Treatment per Day Unless Otherwise Stated Placebo Form ofSupplementation Number of Capsules Duration
b (Weeks)
Healthy
[108] DHASCO a: 400 or 1200 mg DHA Corn oil Capsules 6 8
[106] 800 mg FO: 400 mg DHA, 56 mg EPA Olive oil Chewable capsules 2 16
[113] 670 mg FO Olive oil Capsules 2 16
[110] 2400 mg FO and 600 mg evening primrose oil: 174 mgDHA, 558 mg EPA, 60 mg GLA. Palm oil Capsules 6 28.6
[104] 174 mg DHA, 558 mg EPA, 60 mg GLA Palm oil Capsules 6 12 + 12 (open)
[102] 1260 mg DHA rich oil: 652 mg DHA, 101 mg EPA Placebo oil (656 mg LA, 87 mg ALA) Capsules 6 12
[101] Fish flour: 892 mg of DHA per week Placebo spread contained bread flour Margarine NA 14.9
[107] 14–21 mg DHA, 20–30 mg AA Placebo supplement Sachets to mix into foods 2–3 sachets 30
[103] FO: 3600 mg DHA, 840 mg EPA per week 50% soybean oil, 50% rapeseed oil(4200 mg LA per week) Bread and sausages NA 12
[114] 541 mg FO: 116 mg DHA, 165 mg EPA Sunflower oil Capsules 2 12
[112] DHASCO-S a: 400 mg DHA High oleic sunflower oil Capsules 2 16
[115] FO: 1 g DHA, 200 mg EPA Soybean oil Chocolate milk NA 15.6
[109] 88 mg DHA, 22 mg EPA Unclear Drink NA 52
[105] 500 mg DHASCO-S a: 200 mg DHA, 4 mg EPA Vegetable oil (15 mg ALA,250 mg LA) Capsules 5 8
[111] FO in dairy drink 120 mg DHA, 60 mg EPA Whole milk Milk drink NA 20
[117] 4 g FO: 1.5 g DHA, 1.86 g EPA Corn oil Unclear Unclear 8 + 8 with 4 weekswash-out in between
[100] 3 mL dose of 1200 mg FO: 240 mg DHA, 360 mg EPA. Corn oil Liquid oil NA 12
[88] FO: 125 mg DHA, 230 mg EPA Corn oil Capsules Dependent on bw 16
[96] 3 g O3FA Olive oil Capsules Dependent on bw 52
[92] 1.875 mL FO: 0.75 g of DHA + EPA. If well tolerateddose ×2 after 2 weeks.
Olive oil and medium chain
triglycerides. Liquid oil NA 24
[65] 165 mg DHA, 635 mg EPA, 100 mg other O3FA Olive oil Capsules NS 8
[67,68] 174 mg DHA, 558 mg EPA, 60 mg GLA Olive oil Capsules 6 12 + 12 (open)
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Table 2. Cont.
Reference Treatment per Day Unless Otherwise Stated Placebo Form ofSupplementation Number of Capsules Duration
b (Weeks)
[97] FO and EPO: 174 mg DHA, 558 mg EPA, 60 mg GLA Olive oil Capsules 6 26
[79] 120 mg DHA, 600 mg EPA Olive oil Capsules 2 16
[122] 480 mg DHA, 186 mg EPA, 96 mg GLA, 864 mg LA,42 mg AA, 8 mg thyme oil Olive oil Capsules NR 12
[66] DHA-rich fish oil: 3600 mg DHA 700 mg EPAper week. Olive oil Milk and bread NA 12
[76] 480 mg DHA, 80 mg EPA, 40 mg AA, 96 mg GLA Olive oil Capsules 8 16
[143–145] LCPUFA supplementation: varying dosage Olive oil Capsules 1 per 4 kg of bw 52
[94] Flax seed oil: 0.55 to 6.6 g ALA Olive oil Capsules Varying up to 12 16
[89] FO: DHA 7.3 ± 11.5 mg/kg of bw, EPA17.0 ± 26.8 mg/kg of bw Olive oil Capsules
Dependent on bw:
6–12 43.6
[83] PCSO-524 c: 16.5–22 mg DHA, 21.9–29.2 mg EPA Olive oil, lecithin and coconut oil Capsules Dependent on bw: 3–4 14
[86] Drink containing FO (1.6 g DHA, 3 g EPA) and borageoil (3.0 g GLA)
Control drink with high oleic
safflower oil Drink NA 12
[70] EPA-rich FO: 108 mg DHA, 1,109 mg EPA orDHA-rich FO: 1,032 mg DHA, 264 mg EPA Safflower oil Capsules 4 16 + 16 + 16
[90] FO: 1.1 g DHA + EPA Safflower oil Pudding packet 2 pudding packs 12
[123] FO: 180 mg DHA, 270 mg EPA Soybean oil Capsules 3 12
[135] 2 g FO: 1200 mg DHA + EPA Sunflower oil Capsules 4 24
[87] FO: 1.2 g O3FA Sunflower oil Capsules, salad dressingand margarine 4 24
[72] FO and EPO oil: 592.74 mg O3FA Sunflower oil Capsules 2 26
[58] 1 g FO:120 mg DHA, 180 mg EPA Sunflower oil Capsules Unclear 24
[61] 100–400 mg DHA, 500–100 mg EPA Sunflower oil Capsules Dependent on bw: 2–4 16
[129,130] AO: 450–1300 mg O3FA (DHA: EPA in 3:2 proportion) Sunflower oil Capsules Dependent on bw 24
[116] AO: 500 mg DHA or FO:500 mg DHA + EPA Wheat gern oil Capsules 1 16
[131–133] AO: 250 or 500 mg DHA Germ oil Capsules 1 26.1
[134] AO: 250 mg DHA Germ oil Capsules NR 26
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Table 2. Cont.
Reference Treatment per Day Unless Otherwise Stated Placebo Form ofSupplementation Number of Capsules Duration
b (Weeks)
[95] Algae triacylglycerol 100 mg DHA/kg/day 1st monththen 1 g DHA/day Germ oil Capsules 4 52
[93] AO: 200 mg DHA Corn oil + soy bean oil Capsules 1 26
[146,147] AO: 600 mg DHA Corn oil + soy oil Capsules 3 16
[138,139] 4.9 g FO: 892 mg DHA, 191 mg EPA 6:1:1 mix of palm shortening, soy oil,and rapeseed oil Bread NA 16
[141] 2.5–4 g FO (12% DHA, 18% EPA) Blackcurrant seed oil (45.7% LA, 18%GLA, 14% ALA) Capsules Dependent on bw: 5-8 26
[62] 650 mg DHA, 650 mg EPA Normal margarine (1 g LA) Margarine NA 16
[99] FO: 720 mg DHA, 1080 mg EPA 1800mg lactose Capsules 2 8+8
[125] 200 mg DHA, 1400 mg EPA, 400 mg other O3FA Placebo capsule Capsules 2 12
[136,137] FO and EPO: 290 mg DHA, 930 mg EPA, 100 mg GLA Placebo Capsules 10 12 + 12 with 6 weekswash-out in between
[91] FO: 1.1 g DHA + EPA Identical placebo Pudding packet 2 pudding packs 6
[128] 1000 mg PUFA Placebo Capsule 1 52
[63] 2 g sage oil: 1 g ALA Lactose placebo Capsules 2 8
[60] 240 mg DHA, 360 mg EPA Placebo Capsules 2 8
[64] FO: 2.7 mg DHA, 500 mg EPA Placebo Capsules 1 15
[127] 2.4 g omega-3 Vitamin E or placebo Tablets NR 8
[84] 100 mg DHA, 250 mg EPA, 25 mg phospholipids Sunflower oil Capsules According to bw: 1–2 16
[124] 1 g FO: 120 mg DHA, 180 mg EPA Placebo capsule Capsules 1 At least 8 weeks
[78] Algae oil: 345 mg DHA Placebo capsule Capsules 1 16
[59] 241 mg DHA, 33 mg EPA, and 180 mg omega-6 Identical placebo Capsules 1 10
[118–121] FO: 155 mg DHA, 29 mg EPA Placebo Capsules 2 15
[142] Varying 500–6000 mg O3FA Placebo Capsules Varying up to 12 20
[140] Salmon oil: 360 mg DHA, 540 mg EPA
Placebo (corn starch, lactose,
magnesium stearate and polyvinyl
pyrrolidone)
Capsules NR 4
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Table 2. Cont.
Reference Treatment per Day Unless Otherwise Stated Placebo Form ofSupplementation Number of Capsules Duration
b (Weeks)
[85] 300 mg DHA, 200 mg EPA, 400 mg ALA, 100 mgof DPA Drink without omega-3 Drink NA 24
[77] FO: 96 mg DHA, 153 mg EPA or n-3 LC-PUFAcontaining PLs: 95 mg DHA, 156 mg EPA Rapeseed oil
Chocolate flavoured
spread NA 13.1
[73] 240 mg LA, 60 mg ALA, 95 mg mineral oil Vitamine C capsules Capsules 1 7
[69] FO and EPO: 174 mg DHA, 558 mg EPA, 60 mg LA. Medium chain triglycerides Capsules 6 12
[126] 200 mg DHA 400 mg EPA, or 180 mg DHA,380 mg EPA Olive oil or safflower oil Capsules 1–2 16
[74,75] FO and EPO: 174 mg DHA, 558 mg EPA, 60 mg GLA Palm oil Capsules 6 30
[98] 500 mg ethyl-EPA Triglycerides and cellulose Capsules NR 12.9
[80,81] 1–15 weeks: 120 mg EPA + DHA16–30 weeks: 60 mg EPA + DHA Cellulose Capsules 4 15 + 15
[82] 321 mg DHA, 42.2 g EPA per 100 g egg Ordinary egg Egg 1 13.1
a DHASCO is an algal triglyceride DHA; b Some studies gave duration in months or number of days supplementation was received, we recalculated the duration to weeks; c PCSO-524 is
an lipid extract of the New Zealand green-lipped mussel; bw: body weight, NA: not appropriate, NR: not reported.
Nutrients 2017, 9, 474 11 of 32
Table 3. Recruitment effort and recruitment rates.
Reference Invited Responded/Screened Started Finished
Started/
Invited %
Started/
Responded %
Started/Finished
% Recruitment Method Recruitment Setting Study Period
[141] NS NS 21 21 - - 100 NS Department ofPaediatrics NS
[66] 46 40 40 40 87 100 100 Parents of summer camp participantswere asked.
Summer camp for
children with
psychiatric disorders
NS
[98] 107 107 61 61 57 100 Teachers nominated children withreading difficulties School
Autumn
2005–January 2006
[131–133] NS NS 60 60 - - 100 NS Hospital NS
[115] NS NS 180 180 - - 100 NS School NS
[116] NS NS 36 36 - - 100 NS Hospital 8 month period
[146,147] 1376 675 362 359 26 54 99
Parents of underperforming children
received a letter inviting their children
to take part in the formal
screening assessments.
School NS
[105] NS NS 90 88 - - 98 Via advertising in newspapersand schools
Community
and schools NS
[88] NS 298 197 192 - 66 98
Participants with asthma diagnosis
were recruited from elementary
schools through parent conferences
Schools NS
[82] 1556 1556 179 171 12 12 96 Children were screened from studentsin two township primary schools Schools NS
[62] NS 372 79 76 - 21 96 Via hospital and advertising at schools. Hospital and schools NS
[72] NS 422 98 94 - 23 96 NS Outpatient treatmentprogram NS
[114] NS 408 196 189 - 48 96 NS School NS
[58] NS 100 70 65 - 70 93 NS Hospital NS
[117] NS NS 42 39 - - 93 NS Hospital NS
[118–121] NS 926 321 294 - 35 92 Parents were invited to aninformation meeting. School
November
2009–November
2010
[127] NS NS 90 83 - - 92 NS CardiovascularResearch Centre NS
[60] NS NS 75 69 - - 92 NS Outpatient ADHDclinic 2007
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Table 3. Cont.
Reference Invited Responded/Screened Started Finished
Started/
Invited %
Started/
Responded %
Started/Finished
% Recruitment Method Recruitment Setting Study Period
[103] NS 230 179 166 - 78 92 Via advertisements Community NS
[85] NS 938 200 184 - 21 92 Via parents who themselves hadparticipated in a study.
Participants earlier
study
November
2009–December
2011
[123] NS 59 55 50 - 93 91
Parents were invited to a meeting at
which the study procedures were
explained and a written informed
consent from the tutors and a verbal
assent from their children were
obtained.
School NS
[95] NS NS 41 37 - - 90 NS Hospital NS
[101] NS NS 183 164 - - 90 NS School NS
[138,139] 3652 NS 87 78 2 - 90
Subjects were recruited via addresses
obtained from the Danish Civilian
Person Register.
Community NS
[111] NS NS 119 107 - - 90 NS School NS
[99] NS NS 42 37 - - 88 NS School NS
[134] NS 118 58 51 - 49 88 NS Hospital
May
2012–September
2014
[113] NS 44 33 29 - 75 88 Via public flyers Community NS
[135] NS 30 24 21 - 80 88 NS Hospital NS
[87] NS NS 45 39 - - 87 NS NS Over period of 16mo.
[108] NS 48 38 33 - 79 87 NS NS NS
[112] NS 405 202 175 - 50 87 NS NS NS
[86] NS NS 43 37 - - 86 NS Outpatient clinic NS
[65] NS NS 120 103 - - 86 NS Hospital NS
[97] 189 129 117 100 62 91 86
Letters of invitation were sent to
parents of children who were
identified by teachers.
School NS
[78] NS 250 63 54 - 25 86 Via advertisements Community NS
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Table 3. Cont.
Reference Invited Responded/Screened Started Finished
Started/
Invited %
Started/
Responded %
Started/Finished
% Recruitment Method Recruitment Setting Study Period
[79] NS 334 110 95 - 33 86
Via health professionals, teachers,
leaflets handed out to support groups,
leaflet distributed at community
centres and advertisements in a free of
charge regional newspaper.
Community, Health
professionals, schools,
support groups.
NS
[64] NS NS 109 92 - - 84 NS Hospital and secondarytreatment centres
January 2005–June
2007.
[129,130] NS 86 76 64 - 88 84 NS Hospital 2008-2011
[92] NS 101 38 32 - 38 84 NS Hospital
December
2010–December
2013
[107] NS NS 37 31 - - 84 NS NS NS
[143–145] NS NS 24 20 - - 83 NS NS Recruited over 6month
[125] NS 178 23 19 - 13 83 Via advertisements and clinicianreferrals.
Community and
referral
July 2011–May
2014
[109] NS 932 780 643 - 84 82 Via advertisement at schools andmedia advertisement. Schools
Auguet
2003–April 2005
[136,137] 108 47 31 25 29 66 81 NS. Outpatient clinic NS
[73] NS ~300 78 63 - 26 81
Via advertisement on radio health
program, in health newspapers and in
ADHD clinics.
Community and
ADHD clinic
January 2007–June
2007
[80,81] NS 247 200 162 - 81 81 Advertisements in newspapers, on theInternet and medical centres. Community NS
[91] 863 118 57 45 7 48 79
E-mail invitations to in registry and
longitudinal study of families of
children affected by ASD.
Online registry
18 September
2012–31 December
2012
[67,68] NS NS 75 59 - - 79 NS Hospital October2004–August 2006
[128] NS NS 138 108 - - 78 NS Outpatient clinic March 2010–June2012
[122] NS NS 41 32 - - 78 NS School NS
[106] NS 511 450 348 - 88 77 Via school Schools NS
[89] NS NS 30 23 - - 77 NS Hospital January1994–March 1995
[142] NS NS 33 25 - - 76 Via community, hospital and throughpatient association.
Community and
referral NS
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Table 3. Cont.
Reference Invited Responded/Screened Started Finished
Started/
Invited %
Started/
Responded %
Started/Finished
% Recruitment Method Recruitment Setting Study Period
[69] NS 138 76 57 - 55 75
School and parent group circulated
screening information to all potential
eligible families
Schools and parent
groups NS
[83] NS 351 144 108 - 41 75 NS NS NS
[77] 250 102 83 60 33 81 72 Newspaper advertisement Community July 2004–January2005
[126] NS NS 28 20 - - 71 NS Hospital NS
[93] NS 143 48 34 - 34 71 Via recruitment flyers across campusand sent to autism support groups.
Campus, autism
support groups NS
[61] NS NS 37 26 - - 70 NS ADHD clinic NS
[90] NS 32 27 19 - 84 70 NS Outpatient autism clinic 5 November2008–25 June 2009
[84] NR NR 37 26 - - 70 NS NS NS
[104] NS 162 154 105 - 95 68 Via teachers who informed families School December2009–July 2011
[76] NS 193 50 33 - 26 66 NS Community NS
[74,75] NS 201 167 109 - 83 65 NS NS Start March–May2004
[70] NS 199 96 57 - 48 59
Via media releases, television
interviews, newspaper advertisements,
school newsletters, and flyers.
Community and School June 2007–June2009
[110] 560 447 408 227 73 91 56 Via information sessions and schoolnewsletters. Schools
December
2010–May 2011
[94] NS NS 51 24 - - 47 NS Hospital November2001–March 2005
[63] NS NS 40 17 - - 43 NS ADHD clinic NS
[59] NS NS 40 NS - - - NS Outpatient ADHDclinic
June 2009–March
2010
[124] NS NS 25 NR - - - NS Hospital NS
[140] 142 NS 76 NS 54 - -
From previous sample children with
insulin resistance were identified and
invited
Community NS
[102] NS NS 233 NS - - - Via school School NS
[100] NS NS 70 NS - - - NS Hospital NS
[96] NS NS 38 NS - - - NS Hospital NS
NS = not specified.
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Table 4. Adherence and drop out characteristics per study.
Reference Adherence Assessment Adherence Mean or nr. of Part.Non-Adherent
Blood FA
Determined?
Drop-Out Rate (%)
Treatment Placebo
Healthy
[114] Supervision and tick-off form Active: 88.4%, Placebo: 88.5% Y 3.1 6.1
[115] Supervision NR Y 0 0
[108] NR NR Y Low DHA: 20; HighDHA: 7.1 17
[112] Capsule count Nearly 100% Y 7.1 5.6
[101] Supervision Active: 94.8%, Placebo: 94.5% Y 11 9.8
[106] Pill diary by teacher or parent Active: 68.4%, Placebo: 66.7% Y 24 21
[102] NR NR Y NR NR
[103] NR >90%. Y 6.7 7.8
[109]
Sachet count and diary
(Australia)/Supervision (Indonesia)
Australia: 73-84% Y 27 34
Indonesia: 85-87% 3.6 5.3
[111] Interview small increase in DHA insupplemented group Y NR NR
[107] Diary n = 6 Y NR NR
[105] Parental signing of diary card >80%. N NR NR
[113] NR NR N 5.9 19
[110] Supervision Phase 1: 59%, Phase 2: 61% N 47 42
With disorder or illness
[141] NR NR Y 0 0
[140] Pill count Active: 93%, Placebo: 96% Y NR NR
[82] Supervision
count of consumed eggs showed
good compliance and % of adherence
to treatment was 100%
Y 5.6 3.2
[127] Pill count pill count revealed no essentialirregularities Y 13.3 Vit. E: 0, Placebo: 10
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Table 4. Cont.
Reference Adherence Assessment Adherence Mean or nr. of Part.Non-Adherent
Blood FA
Determined?
Drop-Out Rate (%)
Treatment Placebo
[84] NR NR NR NR NR
[80,81] Pill count n = 14 N 20 18
[83] Pill count, compliance diary andtelephone call 96.7% N 23 23
[95] NR
n = 2 DHA supplementation induced
a median plasma DHA enrichment of
5% suggesting adherence
Y 14 5
[138,139] Interview 90% Y NR NR
[79] Capsule count n = 1 Y 13 11
[86] Diary and blood values 80–85% Y 21.1 11.1
[77] Phone calls and product weighting n = 6 Y Phospholips: 38,Fish oil: 25 24
[118–121] Supervision 95.4% Y 6.9 9.9
[61] Blood NR Y CO CO
[94] Capsule count and diary >75% Y 42 64
[70] Capsule count EPA: 83%, DHA: 86% , LA: 85% Y CO CO
[87] Capsule count 75% Y NR NR
[76] Diary 88% Y 28 40
[143–145] NR NR Y 17 17
[131–133] Capsule count and interview excellent in all groups Y NR NR
[62] Product weighting n = 1 Y 0 5.1
[135] Capsule count and interview NR Y 0 25
[78] Capsule count Active: 96.7%, Placebo: 100% Y 15 13
[93] Capsule count excellent Y 21 38
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Table 4. Cont.
Reference Adherence Assessment Adherence Mean or nr. of Part.Non-Adherent
Blood FA
Determined?
Drop-Out Rate (%)
Treatment Placebo
[136,137] Capsule count n = 1 Y CO CO
[90] Parent interview Active: 69%, Placebo: 75% Y 36 23
[69] Capsule count FA changed in the expected direction. Y 24 30
[89] NR NR Y 27 14
[64] Capsule count NR Y 30 19
[116] Capsule count DHA: 96.5%, DHA + EPA: 96.9%,Placebo: 96.7% Y
DHA: 0, DHA +
EPA: 0 0
[117] Blood value NR Y CO CO
[129,130] Capsule count 95.5% Y 21 11
[128] Capsule count NR Y NR NR
[134] Blood values n = 5 Y 14 10
[98] NR According to parents children tookthe capsules carefully Y NR NR
[88] Supervision and capsule count Pill count: 91% Y 0 0
[92] NR
there was no overlap between the
distributions of plasma levels
between groups at week 24
Y 21 11
[65] Capsule count n = 5 N NR NR
[97] Capsule count and diary Period 1: 88.7%, Period 2: 85.5% N 17 12
[91] Parents e-mail Active: 69%, Placebo: 83% N 28 14
[85] Parent interview and blood values Average number of drink per week6.5. N 10 22
[73] Capsule count Active 7.88 capsules left; Placebo: 14capsules left N 18 21
[125] NR 89–97% N 10 23
[142] NR NR N 18 31
[67,68] Parent interview Period 1: 93.4%, Period 2: 93.3% N CO CO
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Table 4. Cont.
Reference Adherence Assessment Adherence Mean or nr. of Part.Non-Adherent
Blood FA
Determined?
Drop-Out Rate (%)
Treatment Placebo
[126] NR n = 5 N NR NR
[122] Capsule count Active: 90.4%, placebo 86.6% N 23 21
[74,75] Capsule count and diary n = 2 N CO CO
[63] Capsule count NR N 60 55
[59] NR NR N NR NR
[124] NR NR N NR NR
[100] NR NR N NR NR
[96] NR Compliance was optimal N NR NR
[66] NR NR N 0 0
[146,147] Diary At school: 75% N 0.6 1.1
[72] NR NR N 2 6.1
[58] NR n = 5 N 8.6 5.7
[60] NR NR N NR NR
[123] Diary and capsule count NR N 0 20
[104] Interview Active: 94%, Placebo: 92%, Period 2:91% N CO CO
[99] NR n = 1 N CO CO
CO: cross-over study, NR: not reported.
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Looking at the adherence percentage between studies in healthy and diseased children, there
seemed to be a slightly lower average adherence in diseased children (M = 83.7%, SD = 11.9), compared
to healthy children (M = 87.6%, SD = 7.1). When we looked at the different age groups recruited, there
seemed to be a lower average adherence in the child only group (M = 82.5%, SD = 9.5), compared
to adolescents (M = 89.2%, SD = 1.1) or the combined group (M = 88.5%, SD = 11.2). The difference
in average adherence in different recruitment settings was less clear; hospital (M = 86%, SD = 10.6),
community (M = 89.5%, SD = 7.8), and school (M = 83.9%, SD = 11.6). The average adherence
rate also differed between continents with a lower average rate in Australia and USA/Canada:
Europe (M = 87.5%, SD = 9.3), USA/Canada (M = 78.7%, SD = 6.5), Asia (M = 92%, SD = 1.4),
Africa (M = 95%, SD = 0.5), Australia (M = 79.7%, SD = 13.5), and South America (M = 94.5%, just
one study). There seemed to be a tendency for higher average adherence when capsules were used
(M = 88.2%, SD = 8.0) instead of food (M = 74.8%, SD = 14.3) or drinks (M = 81.5%, SD = 9.2), or other
forms of supplementation (M = 80.3%, SD = 18.0). Some studies mentioned that participants took
capsules under supervision, but they did not show a higher mean adherence (M = 82.8%, SD = 15.2)
than those that did not have supervision of capsule intake (M = 86.2%, SD = 8.3). Seven studies,
that reported adherence, reported that participants consumed capsules more than once a day while
12 studies, that reported adherence, mentioned that the capsules were only taken once a day. There
was no difference in average adherence between those two methods of supplementation (M = 87.3%,
SD = 9.4 vs. M = 87.6%, SD = 7.8). Fifteen studies, reporting adherence, mentioned talking to
parents or participants either via telephone or face to face (or via e-mail) during the study about
the supplementation to increase adherence [61,67,69,70,72,90,91,107,111,113,131,134–136,143]. The
studies that included a phone call did not have a higher average adherence rate (M = 81.5%, SD = 9.5)
than those that did not include a phone call (M = 86.2%, SD = 10.3). There were three studies that
provided some form of incentive [98,107,146], however only one of these studies reported an adherence
percentage. Forty-six studies mentioned that they took either blood or cheek samples, but only five
studies mentioned that they used blood as an adherence measure [61,85,86,117,134].
3.5. Drop-Out
Sixty-five of the 75 included studies mentioned a drop-out rate or included numbers which made
it possible to calculate the drop-out rate. The average drop-out was 17% (SD 13%), but it varied
between 0% and 58% (see Table 4). There was no clear difference in average drop-out rate between
studies in healthy (mean = 16.5%, SD = 11.5) and diseased populations (M = 17.9%, SD = 13.7). There
was a difference in average drop-out with regard to the recruited age group: children M = 15%,
SD = 11.1), adolescents (M = 12.3%, SD = 7.3) or both (M = 21.5%, SD = 14.9); with a higher average
drop-out rate in the combined age group.
There was also no clear difference in mean drop-out between recruitment setting: hospital
(M = 15%, SD = 11.1), community (M = 18.2%, SD = 8.6) or school (M = 15.3%, SD = 13). Differences
could be seen in the average drop-out according to the continent on which the study was executed:
Europe (M = 13.3%, SD = 9.8), USA/Canada (M = 23.1%, SD = 11.6), Asia (M = 6.8%, SD = 7.4), Africa
(M = 11.6%, SD = 3.9), Middle East (M = 20.1%, SD = 16.7), Australia (M = 34.9%, SD = 7.8), and
South-America (M = 9.1%, just one study). When looking at different forms of supplementation,
no clear differences in average drop-out rate could be seen: capsules (M = 17.5%, SD = 12.9), food
(M = 14.1%, SD = 14.9), drinks (M = 19%, SD = 13.7), and others (M = 17.9%, SD = 8.4). Eight studies
who reported drop-out rate mentioned that capsules were taken under supervision, this seemed to
lead to somewhat lower average drop-out rate (M = 13%, SD = 15.6), compared to the 57 studies
in which participants did not take the capsules under supervision (M = 17.9%, SD = 15.6). Sixteen
studies that reported drop-out rate divided the capsules over multiple intake moments (M = 17.2%,
SD = 9.3). This did not seem to increase or decrease the average drop-out rate if compared to those
studies that specified one intake moment (M = 17.1%, SD = 13.6). Fourteen studies that noted drop-out
rate reported that they contacted the participants during the study. Studies that did so seemed to
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have a slightly higher average drop-out rate (M = 20.4%, SD = 11.4) than studies that did not contact
participants during the study (M = 16.5%, SD = 14.4). Of the studies that reported giving participants
an incentive, two mentioned a drop-out rate, this was on average 15.3% (SD 20.4). Studies that did not
state an incentive had an average drop-out rate of 17.4% (SD 12.7). Of the 65 studies that mentioned a
drop-out rate, 50 specified a reason for drop-out (six did not have drop-out, and nine did not specify
the drop-out). Fifty-two different reasons for drop-out were mentioned, with the most common reasons
mentioned being lost to follow-up, poor or no compliance or inability to take supplement.
4. Discussion
We conducted a thorough review to examine recruitment, adherence and drop-out rates in n-3
LCPUFA supplementation studies in children and adolescents, in order to identify strategies which
can be implemented to improve those rates. Even though the CONSORT guidelines clearly state what
data need to be included in the report of a RCT, the majority of the included studies did not provide a
flow-chart (55% did not) or the dates defining the period of recruitment and follow-up (70% did not).
4.1. Recruitment
The majority of studies provided minimal details about the recruitment process. The low number
of studies that reported the number of participants that they invited and screened is, however, not
uncommon in research studies as similar numbers were reported by Toerien et al. who studied
129 studies in six major journals [148]. The literature does give some suggestions for methods that
could increase recruitment; for example, telephone calls to those who do not reply, an opt-out system
(participants contact the researchers if they do not want to participate, please do note that this is not
legal in all countries), including incentives, making trials open, and in person recruitment [149]. The
use of clinical referral is also suggested to be related to higher recruitment rates, as most patients will
have a trusting relationship with their doctor [150]. When we looked at the research setting (hospital,
community, school), though, the mean started/invited rate and mean started/responded rate seemed
to be slightly higher in the school setting. However, in the studies that looked at diseased populations,
the average percentage efficiency of started/invited and started/responded was higher than studies
looking at healthy populations (M = 43.5% vs. M = 36.2% and M = 63.5% vs. M = 53.1%, respectively).
It has been shown that in adolescents, giving monetary incentives does improve response rates
and has a positive effect on their willingness to participate in studies [151]. However, the provision of
monetary incentives might be considered unethical in children/adolescents [152,153]. One might thus
consider a form on non-monetary incentive, for example in Food2Learn participants received a cinema
voucher [19]. In the current review, there were only three studies that provided an incentive and
these studies did not have remarkably higher recruitment rates. Hence, more studies that do provide
incentives are needed to elucidate whether or not incentives improve recruitment. Moreover, there are
myriad reasons as to why somebody would or would not participate in a study. There are participant
characteristics which in adults have been associated with a higher chance of non-participation such as
younger age, being male, lower social economic status, and lower education level [154,155]. However,
in the limited number of studies on recruitment in children, no association between age or sex has
been seen, although the education level of parents was associated with higher enrolment rates [5].
Beliefs about the effectiveness of the treatment may also play a role. Examples of reasons as to why
adolescents did not participate informally given in Food2learn included: (1) the belief that n-3 LCPUFA
are not effective in improving health; (2) the belief that they already consume sufficient amount of
n-3 LCPUFA/already eat healthy; (3) the belief that participation will take too much time/effort; and
(4) lack of interest in research in general. These factors should be taken into account during the research
process and it seems wise to include explanations that most people do not get enough n-3 LCPUFA in
their diet as well as elaborating on the possible health benefits of n-3 LCPUFA specific to the age group
being assessed.
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4.2. Adherence
Just 25 studies mentioned a specific adherence percentage, which varied between 60% and 97%
with a mean of 85%. Moreover, most studies included in the current review used indirect adherence
assessment methods (i.e., diaries, interviews, and capsules counts) which are all subject to problems
with reporting bias and errors or intentional manipulation [156]. More direct methods such as the
determination of fatty acid levels in the blood seems to be the most reliable method to assess adherence,
which was done in only five studies. However, it should be noted that taking blood samples in younger
children might not be acceptable for all parents or ethical committees and could therefore lead to lower
recruitment numbers.
In the current review, there was no difference in mean adherence in those studies where
participants received a telephone call to try and increase adherence compared to those in which
participants received no telephone call (M = 81.5% vs. M = 87.7%). There were only three studies that
provided an incentive and only one of these studies provided an adherence percentage, which was
75%. There seemed to be a higher average adherence of capsules (M = 88.2%) compared to other forms
of supplementation (M = 74.8%, M = 81.5%, M = 80.3%, for food, drink and other forms, respectively).
Lastly, there was no difference in the mean adherence between those who took capsules multiple
times a day compared to those who took capsules only once a day (M = 87.3% vs. M = 87.6%). It is
however important to remember that all these findings are based on only 25 studies that mentioned an
adherence rate.
Other studies suggest factors that are associated with higher adherence in children and
adolescents, these include: sociodemographic factors (i.e., older children and older adolescents are
less likely to be adherent, and boys are less likely to be adherent), disease associated factors (i.e., if the
disease also has positive symptoms the person is less likely to be adherent), the belief and attitude
that a person has towards the treatment (i.e., those that belief that the treatment will be effective are
more likely to be adherent), their mood (i.e., those with depression are less likely to be adherent)
and the social context (i.e., those who are supported by family and friends are more likely to be
adherent) [157,158]. Methods to increase adherence rates have also been suggested. Methods that
have been employed to increase adherence include: educating participants about adherence, making
medicine (or supplementation) more palatable, providing incentives/tokens, and involving parents or
schools [159,160]. However, one must take into consideration that the vast majority of studies looking
at which methods can help increase adherence have been executed in a medical setting with patients
requiring medications and these results do not by definition translate to nutritional interventions in
healthy participants or those with diagnosed disorders such as ADHD.
Some suggestions for improving adherence for n-3 LCPUFA supplementation studies may
include: providing sufficient information about the importance of adherence (i.e., explaining the
importance of adherence to get valid results), getting parents involved, and providing appropriate
incentives [159,160].
4.3. Drop-Out
In the current review, the average drop-out was 17% (range 0–58%). Three studies mentioned
some form of incentive [98,107,146] and they reported a slightly lower average drop-out than
those that did not use (or did not report) an incentive (M = 15.3% vs. M = 17.4%). There were
differences in average drop-out rates between continents, with drop-out rates being higher in Australia
(M = 34.9%), USA/Canada (M = 23.1%), and the Middle East (M = 20.1%) compared to Europe
(M = 13.3%), Africa (M = 11.6%) and Asia (M = 6.8%). We can only speculate about explanations for this
difference (e.g., individualistic vs. collective societies) and do point out that these differences have to be
interpreted with caution as the number of studies per continent did differ greatly. A number of methods
to decrease drop-out in studies involving adults has been suggested. They include emphasizing
the benefit of participation, flexible scheduling of appointments, regular positive communication
from the research team to the participants (e.g., birthday and Christmas cards, newsletters, etc.),
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a consistent research staff so participants can build a bond with the researchers, and appropriate
incentives [150,161–163]. Other strategies that have been suggested include decreasing the complexity
of the treatment and limiting the number of follow-up visits to the bare minimum [164]. Furthermore,
a combination of multiple strategies is suggested to be most effective in increasing retention [161,164].
All these methods to decrease drop-out have been studied in adults; more research on methods to
decrease drop-out in children and adolescents in RCT is warranted.
Suggestions for decreasing drop-out in n-3 LCPUFA supplementation trial include: keeping in
regular contact with the participants, providing flexible appointment possibilities, providing incentives
for participants and providing reminders. With regard to the supplement, one should keep the regime
as simple as possible e.g., one (concentrated) capsule per day [150,161–164].
4.4. Strengths and Limitations
Limitations of the current review include the fact that many of the included studies did not report
all data on recruitment, dropout and (assessment of) adherence. Due to the incomplete reporting of
data, results should be viewed with caution. The main advantage of the current review is the fact that
we included all studies investigating n-3 LCPUFA supplementation in children/adolescents regardless
of whether they were healthy children/adolescents or children/adolescents with a disease or disorder.
5. Conclusions
The conclusions drawn are based on minimal reporting from the included studies in this review.
Less than half of the included studies abided by the CONSORT guidelines. Problems with recruitment
and drop-out seem to be common in n-3 LCPUFA supplementation trials in children and adolescents.
However, since the reporting about recruitment, adherence and dropout rates was very heterogeneous
and minimal in the included studies, we cannot provide specific suggestions to improve LCPUFA
supplementation studies in children and adolescents.
6. Recommendations
It is important for future studies to report on recruitment effort and rate, adherence (including the
method of assessing adherence) and drop-out rates according to the CONSORT Guidelines.
Suggestions from other scientific areas to increase recruitment, adherence and minimize drop-out
include: the provision of sufficient information about the importance of adherence (i.e., explaining
the importance of adherence to get valid results), getting parents involved, provision of appropriate
incentives, emphasizing the benefit of participation, being flexible with the scheduling of appointments,
the research team engaging in regular positive communication with the participants, having a
consistent research staff member so participants can build a bond with the researchers and to keep the
supplementation regime as simple as possible.
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